美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Health Innovation Active ETF

33.32

+0.10420.31%

成交量：583

成交額：1.94萬

市值：1,332.60萬

市盈率：- -

高：33.32

開：33.23

低：33.23

收：33.21

52周最高：34.86

52周最低：25.79

股本：40.00萬

流通股本：40.00萬

量比：0.29

換手率：0.15%

股息：0.08

股息率：0.24%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

美國股市動態

興齊眼藥(300573.SZ)：SQ-23082滴眼液獲批開展臨床試驗

興齊眼藥：SQ-23082獲臨床試驗批准，屬2.1類

強生（JNJ）漲1.63% 新款雙周拋隱形眼鏡獲CE認證

翰宇藥業(300199.SZ)：HY3003注射液臨床試驗申請獲受理

默沙東帕博利珠單抗三陰性乳腺癌適應症人群擴展在華獲批

翰宇藥業：HY3003注射液獲臨床試驗申請受理通知書

英硅智能(03696)：公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組

拜耳啓動G蛋白偶聯內流整流鉀通道4研究性抑制劑針對心房顫動患者的II期臨床試驗。

Leerink Partners上調默克目標價至161美元

石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准

石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准

石藥集團：SYH9102注射液獲中國臨床試驗批准，每月給藥一次

百利天恒：宜澤康III期臨床試驗完成首例受試者入組

百利天恒：宜澤康III期臨床試驗完成首例受試者入組

安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率

Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費

Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段

Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利

Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BMED/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.315,"timestamp":1789502400000,"preClose":33.2108,"halted":0,"volume":583,"delay":0,"changeRate":0.0031375335734158388,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"盤前交易","change":0.1042,"latestTime":"09-16 05:33:38 EDT","open":33.23,"high":33.315,"low":33.23,"amount":19399,"amplitude":0.002559,"askPrice":52.97,"askSize":100,"bidPrice":13.4,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789565400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":33.315,"sharesOutstanding":360000,"nav":33.210436,"aum":13284174.4,"dividendRate":0.002392,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.23,"preClose":33.315,"latestTime":"16:10 EDT","volume":6,"amount":199.89,"timestamp":1789503006991,"change":-0.085,"changeRate":-0.002551,"amplitude":0},"volumeRatio":0.294682543474685,"impliedVol":0.0634,"impliedVolPercentile":0.004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.294682543474685,"shares":400000,"dividePrice":0.0797,"high":33.315,"amplitude":0.002559,"preClose":33.2108,"low":33.23,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.315,"eps":0,"divideRate":0.002392,"volume":583,"delay":0,"ttmEps":0,"open":33.23,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":33.33,"twentyDayClose":32.4416,"sixtyDayClose":28.4203},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666576453","title":"美國股市動態","url":"https://stock-news.laohu8.com/highlight/detail?id=2666576453","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666576453?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 01:49","pubTimestamp":1789148968,"startTime":"0","endTime":"0","summary":".N美国东部时间13:30，道琼斯工业平均指数.DJI上涨1.15%，报52,664.99点。标普500指数.SPX上涨1.07%，报7,673.08点；纳斯达克综合指数.IXIC上涨1.21%，报26,397.44点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4S4531CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GME","QQQG","HPE","RKLB","EW","ONB","RWT","EXEL","DLLL","AENT","ADBE","KBWB","CPRT","BDRX","ACVA","KR","PTF","ADBG","AGNG","RENT","OKLO","TNON","DELL","YARW","ORCL","FLR","PANW","TENB","RJF","CIBR","MRNA","FIZZ","SNDQ","WLDR","SORCLmain","IGV","SRFM","LHSW","STX","CNAV","PMTS","HPQ","UCAR","ATO","BMED","CHWY","OKLL","SNDK","IXG","SMR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2666544063","title":"興齊眼藥(300573.SZ)：SQ-23082滴眼液獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544063","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:54","pubTimestamp":1789113276,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布公告，近日，公司收到国家药品监督管理局签发的关于SQ-23082滴眼液的《药物临床试验批准通知书》。SQ-23082滴眼液为公司研发的化学药品2.1类改良型新药。临床拟用于过敏性结膜炎相关的眼痒的治疗。根据改良型新药的有关要求，公司已经完成SQ-23082滴眼液药学及非临床药理毒理学等多方面的研究，研究结果表明SQ-23082滴眼液具有良好的安全性及临床开发价值。目前国内外尚无该眼用制剂产品上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0239","PSYK","IBBJ","BMED","300573","BK0177","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666226544","title":"興齊眼藥：SQ-23082獲臨床試驗批准，屬2.1類","url":"https://stock-news.laohu8.com/highlight/detail?id=2666226544","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666226544?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:47","pubTimestamp":1789112862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBQ","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596063","title":"強生（JNJ）漲1.63% 新款雙周拋隱形眼鏡獲CE認證","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596063","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 21:21","pubTimestamp":1789046500,"startTime":"0","endTime":"0","summary":"金吾财讯 | 强生（JNJ）美股盘前股价震荡上行，最新涨1.63%，报271.4美元。消息面上，强生周四宣布，旗下新款ACUVUE OASYS MAX双周抛复用隐形眼镜已拿到CE认证。该款产品属于ACUVUE OASYS MAX产品线的新品，可在完整14天佩戴周期内保障佩戴舒适度与清晰视力。镜片搭载OptiBlue滤光技术、TearStable锁泪技术以及一类紫外线防护功能，专门面向长时间使用电子屏幕人群的用眼需求设计。上市节奏方面，计划2026年晚些时候率先登陆部分欧洲国家；后续视各地监管审批进度，在2027-2028年进一步拓展市场。目前该产品尚未取得美国FDA批准，暂未在美国市场销售。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LU1228905037.USD","LU1244550494.USD","IE00BN8TJ469.HKD","IHE","FHLC","LU2750360997.AUD","TRUH","BK4532","LU0820562030.AUD","LU2756315318.SGD","LU2133065610.SGD","LU0124676726.USD","LU2456880835.USD","LU2505996509.AUD","RXL","LU0070217475.USD","BK4581","PJP","GDOC","LU1929549753.HKD","BMED","FTXH","BK4592","MEDX","LU1732800096.USD","LU0792757196.USD","LU1674673428.USD","LU0689626769.HKD","IE00BLSP4239.USD","IE00BGHQF631.EUR","LU0345770308.USD","LU0964807845.USD","IXJ","BK4559","LU1043141396.HKD","IE00BVYPNW00.USD","LU2750360641.GBP","IE000BZT7R73.USD","JNJ","LU1291159041.SGD","LU2756315664.SGD","VHT","LU1066053197.SGD","IE00BDGV0183.EUR","JDOC","IYH","LU0820561909.HKD","SG9999001440.SGD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666566579","title":"翰宇藥業(300199.SZ)：HY3003注射液臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666566579","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666566579?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:21","pubTimestamp":1789028518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业 发布公告，公司于近日收到国家药品监督管理局核准签发关于HY3003注射液临床试验申请的《受理通知书》。该项目通过人工智能结合多肽芯片技术筛选得到新型多肽分子，由翰宇药业负责临床前研究、IND申报及后续临床试验开发。HY3003拟用于减重、2型糖尿病、代谢相关脂肪性肝炎等适应症，是公司在代谢疾病领域布局的重磅创新药品种。HY3003项目是翰宇药业与碳云智肽在“AI+多肽”领域深度合作的典范。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","300199","IBBQ","BK0070","BK0188","BK0028","BK0077","PSYK","IBBJ","BMED","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666456659","title":"默沙東帕博利珠單抗三陰性乳腺癌適應症人群擴展在華獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2666456659","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666456659?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:21","pubTimestamp":1789028510,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0985320562.USD","LU0238689110.USD","LU0130517989.USD","LU0098860793.USD","LU2361044949.HKD","JDOC","LU1934455194.USD","SG9999014567.USD","LU0823416689.USD","FTXH","LU0868494617.USD","LU2324357040.USD","LU2491050071.SGD","SG9999001176.SGD","LU1699723380.USD","LU1585245621.USD","LU0965508806.USD","LU1066051225.USD","SG9999002232.USD","SG9999015358.SGD","SG9999001440.SGD","IE00BJT1NW94.SGD","IE000M9KFDE8.USD","TRUH","FHLC","BMED","LU0980610538.SGD","XLV","LU0124676726.USD","LU1989772923.USD","LU1116320737.USD","LU2433249047.HKD","LU1291159041.SGD","LU0689626769.HKD","LU0106261372.USD","LU2357627491.SGD","LU0868494708.USD","LU0289739699.SGD","IE00B2B36J28.USD","LU1037948541.HKD","IXJ","LU1917777945.USD","LU2125909593.SGD","SG9999014575.USD","LU1069347547.HKD","LU0122379950.USD","IE00BJJMRZ35.SGD","BK4588","IYH","LU0266013472.USD","LU1116320901.HKD","LU0234572021.USD","IE00BLSP4452.SGD","LU2112291526.USD","LU2360032135.SGD","LU0320765489.SGD","LU0648001328.SGD","IE00BSNM7G36.USD","IE00BN8TJ469.HKD","LU1061106388.HKD","BK4534","LU1032466523.USD","LU2125154778.USD","LU2106854487.HKD","LU1934455277.USD","LU0965509283.SGD","LU2125909247.SGD","LU0006306889.USD","LU2491050154.USD","LU0432979614.USD","LU2089984988.USD","LU1571399168.USD","IE00BBT3K403.USD","LU0265550946.USD","LU2125154935.USD","LU1035773651.USD","LU1941712264.USD","SG9999001176.USD","LU1923622614.USD","BK4550","LU1934455863.HKD","LU1201861249.SGD","SG9999015341.SGD","LU2468319806.SGD","LU0265550359.USD","LU1066051498.USD","SG9999014542.SGD","LU1066053197.SGD","PAWZ","SG9999002224.SGD","LU1430594728.SGD","LU0203345920.USD","LU2023250504.SGD","RXL","LU1989772840.SGD","LU0208291251.USD","PPH","LU0965509010.AUD","IE00B4R5TH58.HKD","BK4585","BK4007","IE00B1BXHZ80.USD","BK4559","HRTS","LU2491049909.HKD","GDOC","SG9999014559.SGD","IE0009355771.USD","IHE","LU1162221912.USD","LU1941712348.USD","IE00BFTCPJ56.SGD","LU0320765646.SGD","LU1023059063.AUD","LU2023250843.SGD","SG9999013999.USD","LU1093756168.USD","VHT","LU0130102774.USD","LU1983299246.USD","LU1037948897.HKD","LU2361045086.USD","LU1066051811.HKD","LU0859254822.USD","LU0965509101.SGD","LU2361044865.SGD","MRK","LU0058720904.USD","LU0203347892.USD","LU1989771016.USD","LU1057294990.SGD","BK4516","LU1974910355.USD","LU1929549753.HKD","LU0477156953.USD","IE0002141913.USD","LU0942090050.USD","LU0070302665.USD","LU1093756325.SGD","BK4533","LU0211331839.USD","LU0861579265.USD","SGXZ57979304.SGD","IE00BLSP4239.USD","LU2461242641.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666565044","title":"翰宇藥業：HY3003注射液獲臨床試驗申請受理通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2666565044","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666565044?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:12","pubTimestamp":1789027978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","PSYK","IBBQ","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555270","title":"英硅智能(03696)：公司管線中領先的人工智能驅動候選創新藥物 Rentosertib已在針對特發性肺纖維化的III期臨床試驗中完成首例患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555270?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:20","pubTimestamp":1788999632,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英硅智能 发布公告，公司管线中领先的AI驱动候选创新药物 Rentosertib，已于北京协和医院完成III期临床试验的首例患者入组及给药;同日，上海市肺科医院亦完成了其在该试验的首例患者入组。GENESIS-IPF-3为一项评估Rentosertib用于特发性肺纤维化患者的III期临床试验。本试验旨在评估Rentosertib是否能比IIa期研究提供涵盖更大患者群体、且更长时间治疗的临床意义上的获益。Rentosertib透过抑制TNIK，旨在阻断或逆转纤维化进程，为IPF患者提供具备疾病改善潜力的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["OGIG","AQGX","TQQQ","TECY","QQA","AIFD","PBOT","NJUL","LCLG","MDTX","MVPS","WPAI","ARTY","06978","IBBJ","BMED","IBBQ","QMAR","QSWN","DQJN","NOCT","159992","161631","03696","MEDX","MFIG","GPIQ","LNGR","PSYK","QQQX","NBDS","QTOC","FWD","NEWZ","KOMP","TARK","GK","VUSE","QQQ","QID","PSQ","TQQY","CHAT","CPNQ","AIBU","NJAN","AIQU","CWC","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580156","title":"拜耳啓動G蛋白偶聯內流整流鉀通道4研究性抑制劑針對心房顫動患者的II期臨床試驗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580156?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:42","pubTimestamp":1788954150,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","IBBQ","MDTX","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584416","title":"Leerink Partners上調默克目標價至161美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584416","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584416?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:22","pubTimestamp":1788949320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MRK","JDOC","LU0965509101.SGD","UUP","FTXH","LU0238689110.USD","HRTS","SG9999014567.USD","LU2468319806.SGD","IXJ","LU2357627491.SGD","LU0689626769.HKD","LU0098860793.USD","IE00BJT1NW94.SGD","PPH","LU2491049909.HKD","SG9999014542.SGD","PAWZ","UDN","LU1201861249.SGD","IYH","RXL","LU2106854487.HKD","BK4534","LU0980610538.SGD","TRUH","LU0965509283.SGD","IHE","FHLC","LU1941712264.USD","SGXZ57979304.SGD","IE00BLSP4239.USD","XLV","BMED","LU1923622614.USD","GDOC","LU1934455863.HKD","VHT","LU0122379950.USD","LU0234572021.USD","LU0868494708.USD","LU1035773651.USD","LU2125909593.SGD","SG9999015358.SGD","LU2125909247.SGD","LU0203345920.USD","LU0648001328.SGD","LU1066051225.USD","LU1430594728.SGD","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666846135","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666846135","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666846135?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:09","pubTimestamp":1788948562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液(该产品)已获中国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1328277881.USD","IBBQ","LU0315179316.USD","LU0140636845.USD","PSYK","LU1226287792.SGD","LU1152091754.HKD","HK0000165453.HKD","LU1226288170.HKD","BK1191","LU0880133367.SGD","LU0314109678.HKD","LU1813983027.USD","LU0067412154.USD","LU1226287875.USD","IE00B543WZ88.USD","IE0008368742.USD","LU0326950275.SGD","LU1951186391.HKD","IBBJ","IE00BZ08YS42.EUR","LU1226288253.USD","LU1807302812.USD","LU1960683339.HKD","BK1515","LU1226287529.USD","LU1008478684.HKD","BK1521","IE00B5MMRT66.SGD","KURE","LU1993786604.SGD","LU2039709279.SGD","BMED","IE00BZ08YR35.GBP","LU0501845795.SGD","MDTX","IE00BZ08YT58.USD","IE00B031HY20.USD","IE0008369823.USD","LU1152091168.USD","SG9999004220.SGD","LU0072913022.USD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584690","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584690","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584690?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948523,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 公布，该集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226287529.USD","LU1008478684.HKD","LU1152091754.HKD","PSYK","LU2039709279.SGD","LU1993786604.SGD","LU1328277881.USD","LU1813983027.USD","LU0315179316.USD","LU0140636845.USD","IE00B031HY20.USD","01093","LU1226288170.HKD","BMED","IE0008369823.USD","LU0326950275.SGD","LU1152091168.USD","IE00BZ08YS42.EUR","SG9999004220.SGD","LU1226288253.USD","LU1960683339.HKD","LU1807302812.USD","IBBQ","LU1951186391.HKD","LU0501845795.SGD","KURE","LU0067412154.USD","IE00BZ08YR35.GBP","BK1521","IE0008368742.USD","IE00B5MMRT66.SGD","MDTX","BK1515","LU0314109678.HKD","LU0072913022.USD","HK0000165453.HKD","LU1226287875.USD","BK1191","IE00B543WZ88.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU1226287792.SGD","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666845175","title":"石藥集團：SYH9102注射液獲中國臨床試驗批准，每月給藥一次","url":"https://stock-news.laohu8.com/highlight/detail?id=2666845175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666845175?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","MDTX","PSYK","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666898185","title":"百利天恒：宜澤康III期臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666898185","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666898185?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 17:09","pubTimestamp":1788944974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBQ","PSYK","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589136","title":"百利天恒：宜澤康III期臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589136","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589136?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 17:09","pubTimestamp":1788944940,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月9日，百利天恒公告称，公司自主研发的全球首创双抗ADC宜泽康用于不可切除EGFR突变非小细胞肺癌同步放化疗后维持治疗的III期临床试验已完成首例受试者入组。每日经济新闻 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK0239","MDTX","PSYK","IBBQ","IBBJ","BMED","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309213?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1023059063.AUD","IBBJ","IBBQ","AMGN","LU0889565916.HKD","BK4588","LU0320765992.SGD","IBB","LU0868494617.USD","LU0058720904.USD","PSYK","BK4139","PBE","BK4533","BIB","IE0002141913.USD","IE00B4R5TH58.HKD","LU1983299246.USD","IE0009355771.USD","BK4566","LU0109394709.USD","BK4581","SG9999001440.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU2242646821.SGD","LU2468319806.SGD","PJP","LU1571399168.USD","TBXU","BBH","LU2242652126.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","BK4585","IE00B2B36J28.USD","MDTX","IE00BJJMRZ35.SGD","BK4599","LU2112291526.USD","LU0122379950.USD","BK4534","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1934455277.USD","LU0122379950.USD","LU0289739699.SGD","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU2324357040.USD","LU0109394709.USD","LU2087621335.USD","LU2112291526.USD","LU1061106388.HKD","SG9999015986.USD","IBB","LU0320765992.SGD","LU2468319806.SGD","BK4578","ASMB","BK4139","LU1585245621.USD","LU1674673691.USD","LU1023059063.AUD","IE00B19Z3581.USD","BK4550","BBH","BK4568","LU0114720955.EUR","LU1778281490.HKD","IE0002270589.USD","LU1066051498.USD","SG9999015978.USD","BIB","LU0965508806.USD","LU2089984988.USD","MEDI","TMED","LU1674673428.USD","IE00BKVL7J92.USD","LU0889565916.HKD","LU1839511570.USD","LU0058720904.USD","LU1571399168.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","TBXU","LU0965509010.AUD","LU1430594728.SGD","LU0234570918.USD","BK4585","LU1934455194.USD","LU1037948541.HKD","LU1037948897.HKD","LU1934455863.HKD","LU2357627491.SGD","SG9999015945.SGD","BK4532","LU1066053197.SGD","BK4583","IE00BSNM7G36.USD","GILD","LU0823416689.USD","LU0861579265.USD","BK4566","LU0965509101.SGD","LU0882574055.USD","BK4588","LU0965509283.SGD","IE00B3T34201.USD","IBBQ","IE00B7SZLL34.SGD","LU0859254822.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4139","LU0114720955.EUR","LU1057294990.SGD","LU1066051498.USD","LU0058720904.USD","LU1778281490.HKD","LU1674673691.USD","LU1037948541.HKD","LU1023059063.AUD","IE00BZ1G4Q59.USD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1934455194.USD","LU1585245621.USD","BK4550","TBXU","LU2468319806.SGD","SG9999015978.USD","BK4585","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1571399168.USD","LU0965509010.AUD","LU1430594728.SGD","LU1066053197.SGD","BK4583","LU0109394709.USD","LU2357627491.SGD","LU0965509101.SGD","LU0320765992.SGD","BMED","SG9999015952.SGD","LU1674673428.USD","IE00BSNM7G36.USD","BK4588","GILD","TMED","IE00B3T34201.USD","LU0965508806.USD","IE0002270589.USD","MEDI","BIB","LU1061106388.HKD","LU0234570918.USD","IBBQ","LU2087621335.USD","BBH","LU0122379950.USD","ASMB","BK4566","LU0861579265.USD","LU1037948897.HKD","LU1839511570.USD","LU1934455277.USD","LU1934455863.HKD","BK4568","IE00B7SZLL34.SGD","LU0823416689.USD","LU2324357040.USD","BK4578","IBB","SG9999015986.USD","LU0965509283.SGD","LU2112291526.USD","BK4532","LU2089984988.USD","SG9999015945.SGD","LU0859254822.USD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","BK4583","LU2324357040.USD","LU0114720955.EUR","MEDI","SG9999015978.USD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU1839511570.USD","GILD","LU2089984988.USD","LU1037948541.HKD","LU0965509101.SGD","LU0289739699.SGD","LU2112291526.USD","BK4566","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IBBQ","LU1037948897.HKD","BK4578","SG9999015986.USD","LU0965508806.USD","LU2468319806.SGD","LU2087621335.USD","LU2357627491.SGD","BK4139","LU1023059063.AUD","LU0320765992.SGD","LU0882574055.USD","LU1934455277.USD","LU0861579265.USD","IE00BSNM7G36.USD","LU1585245621.USD","LU0122379950.USD","LU0234570918.USD","LU1778281490.HKD","BK4568","LU0889565916.HKD","LU0058720904.USD","LU1674673691.USD","BK4550","LU1061106388.HKD","LU1571399168.USD","BMED","LU1066053197.SGD","IE00B3T34201.USD","IE0002270589.USD","BBH","IE00BKVL7J92.USD","LU1934455863.HKD","BK4585","TBXU","TMED","IE00B19Z3B42.SGD","LU0965509283.SGD","LU0109394709.USD","LU0823416689.USD","LU1057294990.SGD","LU0859254822.USD","SG9999015945.SGD","BK4588","LU1674673428.USD","LU1934455194.USD","IBB","BK4532","LU0965509010.AUD","SG9999015952.SGD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU1934455863.HKD","BK4566","BK4578","LU1066053197.SGD","LU1585245621.USD","IE00B3T34201.USD","IE00B19Z3B42.SGD","LU0122379950.USD","LU0320765992.SGD","BK4550","LU1674673691.USD","LU0861579265.USD","LU0882574055.USD","BK4532","IE00BSNM7G36.USD","LU1037948541.HKD","LU1037948897.HKD","LU1061106388.HKD","LU0114720955.EUR","BK4588","LU1430594728.SGD","TMED","LU2324357040.USD","SG9999015945.SGD","SG9999015986.USD","LU2357627491.SGD","IBBQ","LU0289739699.SGD","BIB","LU0058720904.USD","LU0109394709.USD","MEDI","ASMB","LU0965508806.USD","LU2112291526.USD","SG9999015952.SGD","BK4139","IE0002270589.USD","BK4568","SG9999015978.USD","BK4583","IE00BZ1G4Q59.USD","LU1778281490.HKD","IE00BKVL7J92.USD","LU0965509283.SGD","LU1934455194.USD","LU2087621335.USD","LU2089984988.USD","LU2468319806.SGD","LU1066051498.USD","IBB","LU0823416689.USD","LU1057294990.SGD","LU0965509101.SGD","BBH","LU1674673428.USD","IE00B7SZLL34.SGD","BK4585","LU0859254822.USD","LU1571399168.USD","LU1934455277.USD","LU0889565916.HKD","BMED","LU0234570918.USD","TBXU","GILD","LU0965509010.AUD","LU1839511570.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}